BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ventrus Biosciences, Inc.  

787 7th Avenue
48th Floor
New York  New York  19924  U.S.A.
Phone: 212-554-4267 Fax: 212-554-4314


SEARCH JOBS




Industry
Biotechnology






 Company News
Ventrus Biosciences, Inc.  (VTUS) Receives Date For Type B Pre-NDA Meeting With FDA For DOLIZEM (Diltiazem Hydrochloride Cream) In Anal Fissures 4/4/2014 7:42:43 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Tanks As Anal Fissure Drug Fails In Trial; Stock Down -63.01% At Market Close (February 12, 2014) 2/12/2014 8:16:22 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Completes Enrollment Of Second Pivotal Phase 3 Trial Of Diltiazem Cream (VEN 307) In Patients With Anal Fissure 11/25/2013 9:23:41 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Shows Off Positive Phase 3 Anal Fissures Data; Stock Soars +15.12% at Market Close (September 11, 2013) 9/11/2013 7:25:57 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock 1/30/2013 9:35:44 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Announces $20 Million Financing 1/30/2013 9:27:38 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Reports Third Quarter 2012 Financial Results 11/14/2012 7:39:35 AM    More...
Ventrus Biosciences, Inc.  (VTUS) to Present at the Lazard Capital Markets 9th Annual Healthcare Conference 11/9/2012 10:18:59 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study 11/5/2012 9:32:03 AM    More...
Ventrus Biosciences, Inc.  (VTUS) Appoints JP Benya Vice President, Commercial Operations and Business Development 9/24/2012 9:46:54 AM    More...
1234